Related Experiment Video

Updated: Mar 23, 2026

Assessment of Child Anthropometry in a Large Epidemiologic Study
09:36

Assessment of Child Anthropometry in a Large Epidemiologic Study

Published on: February 2, 2017

28.0K

Addressing Pediatric Obesity in Ambulatory Care: Where Are We and Where Are We Going?

Carine M Lenders1, Aaron J Manders2, Joanna E Perdomo3

  • 1Nutrition and Fitness for Life Program, Department of Pediatrics, Boston Medical Center, Boston University School of Medicine, Vose Hall-3, 88, East Newton Street, Boston, MA, 02118, USA. carine.lenders@bmc.org.

Current Obesity Reports
|April 7, 2016
PubMed

Insights

This review identifies pediatric obesity interventions in primary care settings. It highlights treatment approaches, challenges, and successes, offering solutions for future research and practice.

Area of Science:

  • Pediatric Endocrinology
  • Public Health
  • Primary Care Medicine

Background:

  • Childhood obesity remains a significant public health concern.
  • Previous meta-analyses have excluded primary care studies due to specific criteria.
  • The 2007 Barlow report spurred numerous pediatric obesity intervention studies.

Purpose of the Study:

  • To identify randomized controlled trials (RCTs) for pediatric obesity treatment in primary care settings.
  • To analyze treatment approaches, challenges, and successes reported in these studies.
  • To identify research gaps and propose actionable solutions.

Main Methods:

  • Systematic literature search for RCTs in pediatric ambulatory care.
  • Inclusion of studies focusing on obesity intervention.
  • Thematic analysis of treatment strategies, barriers, and outcomes.

Main Results:

  • Identified various treatment modalities used in primary care settings.
  • Documented common challenges faced during intervention implementation.
  • Reported successes and areas for improvement in pediatric obesity management.
  • Highlighted significant gaps in current research and practice.

Conclusions:

  • Primary care settings are crucial for pediatric obesity interventions.
  • Addressing identified gaps requires targeted research and practical strategies.
  • Urgent action items are needed to improve treatment efficacy and accessibility.

Keywords:
AdolescentsObesityPediatricsRandomized case–control studiesReviewWeight management

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.4K
Physical Activity Measurement in Children Accepting Table Tennis Training06:51

Physical Activity Measurement in Children Accepting Table Tennis Training

Published on: July 27, 2022

2.6K

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
334
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
363
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
317
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
669
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
274